The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling
pathway was discovered more than a quarter-century ago. As a fulcrum of many vital cellular …

Objective: To develop an evidence-based guideline for the pharmacologic and
nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the …

Objective To update the European League Against Rheumatism (EULAR) recommendations
for the pharmacological treatment of psoriatic arthritis (PsA). Methods According to the …

Psoriasis vulgaris is a common, heterogeneous, chronic inflammatory skin disease
characterized by thickened, red, scaly plaques and systemic inflammation. Psoriasis is also …

Background Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the
treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic …

Background Since the publication of the European League Against Rheumatism
recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new …

Psoriasis is a systemic inflammatory disease associated with increased risk of comorbidities,
such as psoriatic arthritis, Crohn's disease, malignancy, obesity, and cardiovascular …

Background Interleukin 17A is a proinflammatory cytokine that is implicated in the
pathogenesis of psoriatic arthritis. We assessed the efficacy and safety of subcutaneous …

Objective To evaluate the efficacy and safety of ustekinumab in 3 randomized, placebo‐
controlled studies in patients with axial spondyloarthritis (SpA). Studies 1 and 2 included …

Abstract Tumor Necrosis Factor (TNF), initially known for its tumor cytotoxicity, is a potent
mediator of inflammation, as well as many normal physiological functions in homeostasis …